티움바이오

321550KOSDAQ자연과학 및 공학 연구개발업

52.8 / 100

Reference Date: 2026-06-10

Financial Score16.0 / 40

News Sentiment20.8 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Plunged 47.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Tium Bio is a biopharmaceutical company founded by a team that successfully developed and licensed the FDA-approved hemophilia treatment Afstyla, focusing on R&D for rare and intractable diseases. The company develops both small-molecule synthetic drugs and biopharmaceuticals, with several drug candidates in clinical trials, including NCE401 and NBP604. In 2024, Tium Bio acquired Petraon Care Lab, a natural cosmetics OEM/ODM firm, and operates Protiom Science, a CDAO company providing specialized biopharmaceutical process development services.

Number of Employees

67people

Average Salary

57.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

4.45Industry Average 3.242.5Point

Higher than industry avg (caution)

ROE

-42.45Industry Average -32.093.5Point

In line with industry avg

Debt Ratio

39.36Industry Average 7.310.0Point

5.4x industry avg (risky)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲59.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲23.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -36.7% (declining, 3yr)

Detailed News Sentiment

6 totalPositive 6Neutral 0Negative 0Average Sentiment Score 83.3

Positive
티움바이오 ‘토스포서팁’, 두경부암 1차 치료 시장서 '베스트인클래.....
티움바이오의 토스포서팁이 두경부암 1차 치료에서 mPFS 10.9개월로 표준치료 대비 경쟁력을 입증했다.
Positive
티움바이오 "토스포서팁 두경부암 효능 확인…임상 반응률 75%"
티움바이오의 토스포서팁이 두경부암 임상에서 높은 반응률(75%)을 보여 긍정적인 임상 결과를 발표했습니다.
Positive
미국종양학회 달구는 항암 신기술…K-바이오 '시험대'
티움바이오는 미국 임상종양학회에서 RAS 저해제 등 혁신적인 항암 기술을 선보이며 글로벌 경쟁력을 강화할 기회를 얻었다.

Detailed Momentum

52-week position1.0Point

Near 52w low (12%, downtrend)

Current 5,590Won52-week high 13,14052-week low 4,535

1-month return0.0Point

1m -47.56% (strong drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-15